Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy

Yong Jung Song, Yi‐Long Wu, Lejie Cao, Jianhua Chen, Zhiyong Ma, Jiuwei Cui, Jie Wang, Hongbing Liu, Jingyan Ding, Min HuAmerican 2019 · DOI

Abstract

Re-challenge with gefitinib is effective and could be a choice for third-line patients after the first-line EGFR-TKI treatment and second-line chemotherapy, especially for the T790M-negative patients.
BibTeX
@inproceedings{song2019efficacy,
  author = {Yong Jung Song and Yi‐Long Wu and Lejie Cao and Jianhua Chen and Zhiyong Ma and Jiuwei Cui and Jie Wang and Hongbing Liu and Jingyan Ding and Min Hu},
  title = {{Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy}},
  booktitle = {American},
  year = {2019},
  doi = {10.1097/coc.0000000000000538},
}

Loading related content...

Figure